A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer

Progression-free survival (PFS)

Defined as time since initial diagnosis and treatment with nivolumab to either the first disease progression date or last known tumour assessment date, or death due to any cause, whichever occurs first.

Time frame: From initial diagnosis and treatment with nivolumab until date of death due to any cause, assessed up to 36 months

Overall response rate (ORR)

Defined as investigator assessed complete response, partial response, stable disease, or progressive disease.

Time frame: From initial diagnosis and treatment with nivolumab until date of death due to any cause, assessed up to 36 months

Duration of response

Defined as time from response to progression

Time frame: From initial diagnosis and treatment with nivolumab until date of death due to any cause, assessed up to 36 months

Incidence of Adverse Events (AEs)

Time frame: From initial diagnosis and treatment with nivolumab until date of death due to any cause, assessed up to 36 months

Overall Survival (OS)

Defined as time since initial diagnosis and treatment with nivolumab until date of death due to any cause.

Time frame: From initial diagnosis and treatment with nivolumab until date of death due to any cause, assessed up to 36 months

OS measured by Programmed Death-Ligand 1 (PD-L1) combined positive score (CPS)